A c c e p t e d m a n u s c r i p t ACCEPTED ARTICLE PREVIEW
INTRODUCTION
Oncolytic virotherapy is based on the concept that a replicating virus introduced into a tumor will rapidly spread through and lyse that tumor, with targeted replication being possible through natural, or engineered, selectivity 1 . Encouragingly, several viruses are currently entering later stage clinical trials and a randomized phase III study (OPTiM) using herpes simples virus (HSV) therapy for melanoma has achieved its primary endpoint, with a durable response rate of 16% seen in patients receiving HSV, compared with 3% in the control arm 2 . Trials of this sort have also highlighted the multi-component role of the immune system on the efficiency of virotherapy.
Thus, anti-viral immune responses clearly impair virus delivery to tumors following systemic administration and can restrict replication/oncolysis [3] [4] [5] . On the other hand, virus replication does not always correlate with therapy 6, 7 and tumor clearance often requires immune effectors against tumor 8, 9 and/or virus 4, 6-11 . However, a major clinical challenge remains the development of protocols for systemic delivery, in the presence of an intact immune system, to metastatic tumors 1, [12] [13] [14] . In this respect, many barriers to efficient systemic delivery exist, including the tumor vasculature [15] [16] [17] , virus inactivation (including by neutralizing antibody (NAb)), mislocalization, sequestration, and inadequate extravasation 13, [18] [19] [20] .
In our own studies, we have developed the use of reovirus as a systemically delivered oncolytic agent in both pre-clinical models 9, 13, [21] [22] [23] [24] [25] [26] and in early Phase clinical trials 14, [27] [28] [29] [30] . Reovirus has direct oncolytic activity against many human/murine tumor cells 29, 31 , partly because of disruption of the PKR-mediated anti-viral response in malignant cells 32, 33 . In addition, we have shown that anti-tumor therapy is directly associated with immune activation by virus replication in tumors 24, 25 . To mimic the clinical challenges of systemic delivery of oncolytic viruses, we developed a murine model in which injection of reovirus into subcutaneous (s.c.) B16 melanomas generates therapy, but intravenous (i.v.) reovirus does not 13 . However, we demonstrated that i.v. virus could achieve significant activity by conditioning the host with immune modulators (IL-2/Treg depletion or cyclophosphamide [CPA]) 13, 21, 22 , or by conditioning the tumor vasculature for strategies which require in vitro expansion of carrier cells, which are subsequently loaded with a replicating oncolytic virus, prior to intravenous (i.v.) delivery, are currently expensive and complex from a regulatory perspective.
From our ongoing clinical program, we have shown in a Phase Ib, biological endpoint clinical study (REO13) that, following i.v. injection of reovirus prior to planned resection of colorectal cancer liver metastases, reovirus could be specifically detected in patient tumors at the time of surgery, in spite of the presence of NAb in the circulation at baseline in all patients 38 . Moreover,
The REO13 study also demonstrated that, after systemic reovirus administration, replication competent virus could be retrieved from mononuclear cells, granulocytes and platelets within patient blood, but not from the plasma. These data suggested that, although free reovirus is rapidly neutralized by NAb following i.v. injection, it may be successfully transported to tumors via protective carriage by blood cells. Therefore, based on these clinical observations, we hypothesized that i.v. injection of reovirus results in rapid adhesion to, or infection of, blood cells which can protect the virus from neutralization, including by NAb; moreover, it may be possible to stimulate specific cell compartments prior to i.v. virus injection such that virus adhesion occurs selectively to a population of cell carriers which can traffic, and deliver virus, to tumors.
Consistent with this hypothesis, we show here that, following i.v. administration into mice, reovirus associated predominantly with CD11b+ cells, and that stimulation of this compartment with GM-CSF prior to reovirus delivery significantly enhanced anti-tumor therapy by an immunemediated mechanism dependent on both NK cells and monocytes/macrophages. Interestingly, however, GM-CSF conditioning therapy was most effective in the presence of pre-existing NAb.
Our data are significant in that they show that pre-existing NAb to an oncolytic virus may actually be exploited for systemic delivery to tumors and extend the previous use of ex vivo A c c e p t e d m a n u s c r i p t loaded cell carriers to a new concept of directed in vivo cell loading, thereby representing a readily testable, and translatable, method to enhance systemic delivery of oncolytic viruses in patients.
RESULTS

Systemic delivery of reovirus in the presence of neutralizing antibodies
Similar to the findings of our biological endpoint clinical study 38 , 2 minutes after i.v. injection of reovirus, infectious virus was recovered from both plasma and cells of non reovirus-immune mice, but could only be recovered from the cellular fraction in virus-immune mice (Fig. 1A) . By 30 minutes after infusion, although very low levels (non-immune), or no (virus-immune), virus was recovered from plasma, infectious virus was still associated with the cell fraction, with significantly increased levels recoverable from blood cells from virus-immune mice compared to mice with no NAb (p<0.01) (Fig. 1A) . Moreover, substantial levels of infectious virus were still recovered from blood cells up to 1 hour following injection of virus in both groups, although the difference between virus immune and non-immune mice was reduced by this time point (p=0.05) (Fig. 1A) . At 30 minutes post virus injection, ~75% of the cell-associated reovirus recovered from virus-immune mice was in the CD11b+ cell (monocyte/macrophage) fraction (Fig. 1B) . These data suggest that, although free virus is rapidly nullified in the circulation, blood cells, and predominantly CD11b+ cells, might protect virus for potential delivery to tumors.
Reovirus/neutralizing antibody complexes remain available for transfer to tumor cells
Consistent with the hypothesis that CD11b+ cells may act as in vivo carriers for reovirus delivery to tumors, anti-reovirus NAb abrogated productive reovirus infection of B16 tumor cells, PDCA+ dendritic cells (DC) and T cells in vitro. In contrast, productive infection of CD11b+ cells was maintained in the presence of NAb ( Fig. 2A,B ). CD11b+ cells, DC and T cells, pre-loaded with reovirus, were all able to hand virus off to B16 cells upon co-culture (Fig. 2C) , with no significant inhibition by NAb (Fig. 2D) , consistent with our previous observation that murine T cells and DC all under these conditions. In contrast, CD11b+ cells loaded with NAb/reovirus complexes still efficiently passed virus on to tumor cells (Fig. 2E) . Taken together, these data show that NAb does not prevent direct infection of CD11b+ cells and that reovirus taken up in the form of NAb/reovirus complexes by this same population, remains available for hand-off to tumor cells.
GM-CSF mobilization of CD11b+ cells into tumors in vivo
CD11b+ cells appeared to form the major potential depot for sequestration of reovirus and NAb/reovirus complexes following i.v. injection ( Figs. 1 and 2) . Therefore, as a prelude to loading these cells in vivo with i.v. injected virus, we first tested whether it would be possible to use cytokine pre-conditioning to enhance their numbers and subsequent trafficking into tumors.
Reovirus-immune mice bearing 10 day established subcutaneous (s.c.) B16 tumors, were conditioned with 3 daily injections of GM-CSF, a cytokine known both to mobilize CD11b+ cells in vivo and to have potent anti-tumor vaccinating effects 39, 40 . This treatment significantly increased infiltration of CD11b+ cells into tumors compared to PBS treatment (p<0.01) (Fig.   3A) . Furthermore, conditioning with GM-CSF, followed by 2 daily injections of reovirus, increased viral delivery to the tumors (Fig. 3B) , a finding consistent with GM-CSF enhancing CD11b+ cells as in vivo carriers of i.v. injected reovirus into tumors. Importantly, no toxicity was seen in any mice with any of the treatments in this or other in vivo experiments in this study. (Fig. 4A) . By contrast, where mice with 3d established s.c. B16 tumors were immunized with reovirus two weeks prior to tumor implantation and, therefore, had high anti-reovirus NAb, between 80-100% were free of detectable tumor long term following a single cycle of GM-CSF/REO (Fig. 4A) . However, virus-naive, as well as preimmune mice, bearing 5 day established tumors were treated very effectively (p<0.0001 compared to reovirus-immune, or na•ve, controls alone) by giving 3 cycles, rather than just 1, of GM-CSF/REO (Fig. 4B) . In separate studies, we found that the maximal NAb response to reovirus is achieved by day 7-9 after the first reovirus injection (Fig. 4C) , which is consistent with the timing of peak NAb levels in patients 38 . Therefore, we believe that the ability of 3 cycles of GM-CSF/REO to treat virus na•ve mice was probably due to the generation of high levels of NAb as a result of the first cycle of reovirus treatment, which effectively means that the second and third cycles were being delivered to reovirus immune animals. Consistent with this hypothesis, a single cycle of GM-CSF/REO was ineffective as a treatment in mice previously vaccinated with the completely separate Vesicular Stomatitis Virus (VSV) (Fig. 4D) ; however, 3 cycles of GM-CSF/REO were still able to treat 5 day established s.c. B16 tumors in mice previously vaccinated with VSV, although significantly less well than if the mice had no competing anti-viral antibodies prior to treatment (p=0.01 compared to treatment of virus na•ve or only reovirus-pre-immune mice) (Fig. 4B) . 3 cycles of GM-CSF/REO were also effective at treating large, 10 day established s.c. B16 tumors (p<0.0001 compared to GM-CSF or reovirus alone) in virus-immune mice, although fewer mice were free of detectable tumor long-term compared to when treatment was initiated at a smaller tumor size (Fig. 4E) . Importantly, therapy in all of these models was only effective when GM-CSF preceded reovirus (not shown).
GM-CSF conditioning with systemic reovirus eliminates small tumors
A c c e p t e d m a n u s c r i p t
GM-CSF-activated immune cells are cytotoxic to reovirus-resistant tumor cells in the presence of NAb-reovirus complexes
We used the B16ova variant of B16, which we have previously shown to be largely resistant to oncolysis by reovirus due to low expression of the viral receptor JAM-A 25 , to separate direct viral cytotoxicity from immune-mediated cytotoxicity against tumor cells. When immune effector cells from pooled lymph node cells and splenocytes from C57Bl/6 mice, were co-cultured with B16ova cells expressing GFP (B16ova-GFP) alone, minimal cytotoxicity was seen relative to controls (not shown) (designated 100% survival of GFP+ve B16ova cells) (Fig. 5Aa) . The addition of reovirus led to immune-mediated killing of ~42% of the B16ova-GFP cells, leaving ~58% alive (Fig. 5Ab) , consistent with the innate cytotoxicity of reovirus-activated human mononuclear cells against human melanoma cell lines in vitro 41 . Treatment of the LN/splenocyte cells with GM-CSF alone did not stimulate immune cytotoxicity against B16ova-GFP in the absence of reovirus (Fig. 5Ac) , though ~57% of the tumor cells were killed by immunemediated cytotoxicity in the presence of reovirus together with GM-CSF (Fig. 5Ad) ie similar levels to that seen with reovirus alone in Fig. 5Ab . Pre-incubation of reovirus with NAb completely abrogated the reovirus alone-induced immune killing of B16ova-GFP cells in culture ( Fig. 5Ab vs 5Ae) ; however, treatment of LN/splenocytes with GM-CSF, followed by incubation with NAb-reovirus immune complexes, led to killing of >98% of the target tumor cells (Fig. 5Af) .
GM-CSF activated LN/splenocytes also appeared to be cytotoxic in the presence of reovirus pre-incubated with NAb against VSV ( Fig.5Ag ) (albeit less so than with anti-reovirus NAb), although this effect was not reproducibly significant ( Fig.7B ). The NAb-reovirus immune complex-induced cytotoxicity was not affected when GM-CSF-activated LN/splenocyte cultures were depleted of either CD4 or CD8 T cells, but was completely inhibited by depletion of either NK cells or CD11b+ cells (Fig. 5B) . In addition, the cytotoxicity could be reconstituted only by the addition of both NK cells and CD11b+ cells together, but not separately (Fig. 5C) .
A c c e p t e d m a n u s c r i p t
Separation of the GM-CSF-activated LN/splenocyte cultures and the B16ova-GFP targets in transwells prevented any killing of B16 tumor cells in the presence of NAb-reovirus complexes (data not shown). Finally, cytotoxicity of GM-CSF-activated LN/splenocyte cultures against B16ova-GFP targets in the presence of NAb-reovirus complexes correlated with the production of TNF-in the co-cultures, which was again dependent upon the presence of both NK cells and CD11b+ cells (Fig. 5D ).
GM-CSF conditioning enhances Fc receptor expression and NAb-reovirus immune complex transfer from CD11b+ cells
To further explore the mechanism(s) by which GM-CSF may enhance reovirus therapy in the Fig. 6C) . However, pre-incubating with serum from VSV-vaccinated C57Bl/6 mice prior to loading with NAb-reovirus immune complexes, significantly inhibited transfer of infectious virus from both non-conditioned and GM-CSF-conditioned CD11b+ cells to target B16 cells (Fig. 6C ).
These data suggest that GM-CSF-enhanced Fc receptor expression mediates the association of NAb-reovirus immune complexes with CD11b+ cells, which is then responsible for the ability of infectious reovirus to be transferred to target tumor cells both in vitro ( to direct viral induced cell killing of the highly reovirus-sensitive B16tk cell line, but much less so against the relatively reovirus-insensitive B16ova (Fig.7A,B) . However, reovirus complexed with NAb against itself was still highly potent in activating GM-CSF-activated splenocyte/LN cultures to kill both B16ova (as in Fig.5Af ) and B16tk targets (Fig.7A,B) . Consistent with the data of Figs.5D&6A, these effects were largely blocked by either an anti-FcR antibody or by a neutralizing anti-TNF- antibody (Fig.7A,B) .
A c c e p t e d m a n u s c r i p t Cytokine conditioning is dependent on monocytes/macrophages and NK cells in vivo, and is widely applicable
Anti-tumor activity of GM-CSF/reovirus therapy in reovirus-immune mice was dependent upon both NK cells and Ly-6C+ve cells (expressed on neutrophils and monocytes), but not on Ly6G+ve (expressed on neutrophils), as well as on NK cells (Fig. 8A) , confirming that key effector cells for GM-CSF conditioning were monocytes/macrophages rather than granulocytes.
Moreover, the efficacy of GM-CSF/reovirus therapy was not restricted to the B16 melanoma model, because 3 cycles of GM-CSF/reovirus eliminated detectable tumor in 7 of 8 reovirusimmune mice bearing 5d established, s.c. TC2 prostate tumors; no elimination of detectable tumors was seen in mice treated with either GM-CSF or reovirus alone (Fig. 8B) . Finally, based on the success of GM-CSF pre-conditioning, we also screened other clinically-applicable cytokines for possible use as an adjunct to systemic delivery of reovirus. In this respect, although not as effective as GM-CSF, pre-conditioning of pre-immune mice bearing s.c. B16
tumors with IL-2 prior to i.v. reovirus generated survival advantage (p=0.02) over cytokine alone (Fig. 8C) We confirmed that, following i.v. administration in reovirus-immune animals, reovirus was recovered from the cellular, but not the plasma, fractions of blood, consistent with our findings in our clinical REO13 study (Fig. 1) . The majority of viral retention was by CD11b+ cells (which in mice is expressed mainly on monocytes/macrophages but also by other cell types including MDSC), again consistent with our clinical findings, in which the highest titer of virus was retrieved from mononuclear cells. Interestingly, CD11b+ cells, unlike T cells or DC, could be infected by reovirus even in the presence of NAb (Fig. 2B) . Although all 3 populations protected pre-loaded virus from NAb for productive infection of target tumor cells (Fig. 2D) , CD11b+ cells were most effective at handing off pre-formed NAb-reovirus complexes to target tumor cells (Fig. 2E) . Taken together, these data showed that NAb does not prevent direct A single cycle of pre-conditioning with GM-CSF, followed by reovirus, eliminated detectable tumor in most mice bearing 3-5 d established melanomas, but only in mice which were already pre-immune to the virus (Fig. 4A) . These data were initially surprising, given the paradigm that anti-viral NAb act to block viral delivery in vivo and will, therefore, compromise, rather than enhance, oncolytic viral therapy. W e have seen that this is clearly the case in the absence of pre-conditioning with GM-CSF, where the presence of NAb decreased the low levels of i.v.
reovirus that reach s.c. B16 tumors 13 . Nonetheless, the presence of pre-existing NAb -even without GM-CSF conditioning -did not completely ablate systemically administered reovirus from reaching tumors either in mice (Fig. 3B) or in patients 14, [27] [28] [29] [30] . However, the combination of GM-CSF pre-treatment, with pre-existing NAb prior to virus administration, enhanced virus delivery to tumors by up to 2 logs (Fig. 3B) , indicating that GM-CSF was either enhancing the levels of potential virus carrier cells, the phenotype of the virus carriers, or both. These results may also be consistent with those in which an autologous, cell-based, rhabdovirus-infected antileukaemia vaccine was more effective if animals were already virus-immune, although the mechanism in that model remains undefined 46 . In direct support of the critical role of preexisting NAb in these therapeutic effects, the significant difference of efficacy between preimmunised, and virus-naive mice (or mice initially vaccinated against a different virus), was diminished after multiple cycles of GM-CSF/reovirus (Fig. 4B ). This correlated with the appearance of anti-reovirus NAb following the first treatment cycle, which provided the necessary anti-viral vaccination to improve subsequent rounds of therapy (Fig. 4C) .
To investigate any adjuvant immune-activating contributions of GM-CSF treatment to overall anti-tumor efficacy, we used a variant of B16 which is relatively resistant to direct reovirus B16ova-GFP cells in vitro most effectively, when they were first activated with GM-CSF and then incubated with NAb-reovirus complexes (Fig. 5Af) . A similar, though less potent, effect was seen when reovirus was mixed with anti-VSV NAb (Fig. 5Ag) for killing activated by GM-CSF/NAb-reovirus, and cytotoxicity correlated with the production of TNF- (Figs. 5B-D) ; moreover, GM-CSF enhanced Fc R1 expression on CD11b+ cells and increased the ability of isolated CD11b+ cells to pass infectious reovirus from NAb-reovirus complexes to tumor cells (Fig. 6) . In contrast to the positive effect of anti-VSV NAb mixed with reovirus enhancing the cytotoxicity of immune effectors (Fig. 5Ag) , anti-VSV NAb inhibited transfer of NAb-reovirus complexes from CD11b+ cells to target tumour cells (Fig. 6C) ; hence the effects of irrelevant NAb are likely to be various in vivo, and may differ with regard to handoff of replicating virus (inhibitory), and immune-mediated therapy (activating). Overall, these in vitro findings were consistent with differential in vivo depletion studies, which showed that NK cells and monocytes/macrophages, but not granulocytes or CD4/CD8 cells, were required for effective therapy using GM-CSF conditioning followed by systemic reovirus administration (Fig.   8A ).
Finally, we showed that prostate tumors, as well as melanoma, could be treated effectively in pre-immune mice with GM-CSF followed by reovirus (Fig. 8B) , and that IL-2 (but significantly not G-CSF) enhanced therapy, although not as effectively as GM-CSF (Fig. 8C) . This is consistent with a predominant role for monocytes/macrophages rather than granulocytes/T cells as innate effectors in reovirus immunovirotherapy. Experiments are now underway to test whether cytokine conditioning, with GM-CSF or other cytokines, is effective with oncolytic viruses other than reovirus, and the range of tumor types and anatomical locations against which such a strategy is effective.
A c c e p t e d m a n u s c r i p t
Our results here are significant in several respects. First, they extend the previous use of ex vivo loaded cell carriers 12, 26, 34, 35, 47 to generate a new concept of directed in vivo cell loading.
Clinically, the ex vivo expansion and loading of cell carrier populations is time consuming, expensive, and challenging from a regulatory perspective; however, directed in vivo cell loading offers a potentially simpler, cheaper and effective way to enhance systemic delivery of oncolytic viruses with, at least in the models reported here, considerable anti-tumor efficacy. Second, our data also raise the intriguing possibility that manipulation of pre-existing NAb to an oncolytic virus may actually be exploited for systemic delivery to tumors. For example and paradoxically, our results predict that pre-vaccination of patients (along with subsequent cytokine conditioning), prior to i.v. treatment with oncolytic viruses, may lead to significantly more effective delivery of oncolytic viruses to patient tumors and therapy, than without prior induction of NAb. Interestingly, such a pre-vaccination step was mandated in the highly encouraging
OPTiM trial of T-Vec (whose primary clinical endpoint has been met), in which an HSV oncolytic virus was engineered to express GM-CSF, although the rationale there was to limit viral toxicity rather than to improve therapy. Finally, since both GM-CSF and reovirus have been used extensively in patients, clinical testing of the GM-CSF/reovirus regimen represents a readily testable and translatable protocol.
In summary, our data are consistent with a model in which cytokine pre-conditioning expands and activates a population of immune cells which can then be loaded directly in vivo with systemically delivered reovirus (Fig. 9) . Thus, a combination strategy of pre-treatment with GM-CSF, followed by systemic administration of reovirus, offers a promising alternative to ex vivo cell loading, or intra-tumoral injection of oncolytic viruses for the treatment of cancer which, paradoxically, may be enhanced by the presence of anti-viral NAb. W e are currently taking this readily testable approach forward into the clinic, by building on our pre-existing platform of clinical trials using systemic delivery of reovirus 14, [27] [28] [29] [30] . Reovirus. Wild type reovirus type 3 (Dearing strain) stock titers were measured by plaque assays on L929 cells 14, 38 . For in vivo studies, reovirus was administered i.v. at 2x10 7 TCID 50 per injection. For virus titration from tumors, tumors were harvested from mice, weighed, and lysed (3 freeze-thaw cycles within 2 hours of removal). Virus in lysates was titered on L929 cells and expressed as TCID50/mg tissue 13 .
MATERIALS AND METHODS
Cell
In vivo experiments. 6-8 week old female C57Bl/6 mice were purchased from Jackson TCAGCTCTGGGATGACCTTG.
MTT assay. 10 3 B16tk or B16ova target cells were seeded into wells in triplicate in a 96-well plate. 10 4 mixed splenocytes/lymph node cells from C57Bl/6 mice were added per well and treated ± GM-CSF at 10ng/ml. After 24hrs reovirus, reovirus/anti-reovirus NAb or reovirus/anti-VSV NAb were added at MOI 1. In addition, some co-cultures were incubated with the anti-TNF-Ab (AF-410-NA, R&D systems, at 0.5µg/ml) or with the anti-FcR CD16/CD32 antibody (2.4G2 (BD Pharmingen) at 1µg/million cells). 24hrs later, cultures were washed x3 with PBS to remove non-adherent cells and cell killing was assayed using an MTT assay (Cell Proliferation Kit I, Roche) according to the manufacturer's instructions; absorbance was read at 540nm.
A c c e p t e d m a n u s c r i p t
Reovirus infection of CD11b and B16 cells. 10 4 magnetic bead purified CD11b or B16 tumor cells were seeded in triplicate wells of a 96 well plate, treated for 24hr with 10ng/ml GM-CSF and then infected with reovirus at MOI 1 in the absence or presence of reovirus NAb. 2hrs later cells were washed x3 in PBS to remove free virus and the cells were cultured in fresh medium.
Cells and supernatants were harvested at 0, 24, 48, 72, 96, and 120 hrs post-infection and reovirus titers were determined by plaque assay on L929 cells.
Statistics
Survival curves were analyzed by the Log-Rank test. All other data were analyzed by the 2-tailed t-test. Statistical significance was set at p<0.05 for all experiments. 
